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Efficacy and safety of dabigatran versus warfarin in patients with non-valvular atrial 
fibrillation 
WCY Lau, EW Chan, ICK Wong 
The University of Hong Kong, Hong Kong, Hong Kong 
Dabigatran, a direct thrombin inhibitor, is the first new oral anticoagulant approved for the 
prevention of stroke in patients with non-valvular atrial fibrillation (NVAF) as an alternative to 
warfarin. However, the clinical effectiveness and adverse events concerning the use of 
dabigatran are not well described outside clinical trial setting. The aim of this study was to 
compare the efficacy and safety of dabigatran and warfarin in patients with NVAF in the real-
world clinical practice. 
 
Patients newly diagnosed with NVAF from 2010 through 2013 and received dabigatran or 
warfarin were identified from the Clinical Data Analysis and Reporting System (CDARS), a 
population-wide database managed by the Hong Kong Hospital Authority which serves over 
seven million people in Hong Kong. The outcomes of interest were occurrence of ischaemic 
stroke, intracranial haemorrhage (ICH), gastrointestinal haemorrhage (GIH), and all-cause 
mortality among the treatment groups. Patients with history of any outcomes were excluded 
from the analysis. Propensity-score (PS) matching at 1:1 ratio and cox proportional-hazards 
regression were used to compare the risk of outcomes in terms of hazard ratio (HR) between 
treatment groups. 
 
Preliminary results indicated that 4049 and 1281 eligible patients receiving warfarin 
and dabigatran were identified from CDARS respectively. Of these, 1261 PS-matched 
pairs were included in the analysis. The use of dabigatran was associated with a 
reduced risk of ICH (HR=0.25; 95% confidence interval [CI]=0.07-0.89) and all-cause 
mortality (HR=0.58; 95%CI=0.37-0.92) when compared to warfarin, with no significant 
differences in the risk of GIH (HR=1.08; 95%CI=0.63-1.86) and ischaemic stroke 
(HR=0.86; 95%CI=0.51-1.47). In the subgroup analysis for the elderly population 
(age≥75), similar results were found (Table 1). In conclusion, this study showed that the 
use of dabigatran was associated with a lower risk of ICH and all-cause mortality; and 
similar risk of GIH and ischaemic stroke when compared to warfarin. 
 
 
Table 1 Results of the cox proportional-hazards regression analysis after propensity-score 
matching 
 Overall cohort  Elderly population (age≥75) 
 
Dabigatran (n=1261) vs. 
Warfarin (n=1261) 
 Dabigatran (n=662) vs. 
Warfarin (n=662) 
Outcomes Hazard ratios 95% CI  Hazard ratios 95% CI 
Ischaemic stroke 0.86 (0.51-1.47)  0.58 (0.28-1.22) 
Intracranial haemorrhage 0.25 (0.07-0.89)*  0.17 (0.04-0.75)* 
Gastrointestinal haemorrhage 1.08 (0.63-1.86)  1.56 (0.83-2.93) 
All-cause mortality 0.58 (0.37-0.92)*  0.39 (0.22-0.68)* 
*p<0.05. 
 
